Quantcast

Latest Lupus erythematosus Stories

2014-03-25 08:29:48

HERZLIYA, Israel, March 25, 2014 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today announced the appointment of Daniel J. Wallace, MD and Murray Urowitz, MD, two experts in rheumatology, as consultants for the planned Phase II trial for the Company's hCDR1...

2014-03-18 23:02:43

Discounted research study “PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022” elaborated by GlobalData is now available at MarketPublishers.com. According to the report, new product launches are set to fuel SLE and LN treatment markets expansion through to 2022. London, UK (PRWEB) March 18, 2014 The systemic Lupus Erythematosus (SLE) treatment market in the 7 major nations (the US, Germany, France, the UK, Italy, Japan,...

2014-02-04 16:29:30

Lupus Research Organizations Welcome Big-Science Push to Drive New Therapies for Lupus Patients NEW YORK, Feb. 4, 2014 /PRNewswire/ -- The Alliance for Lupus Research (ALR) and the Lupus Research Institute (LRI) are proud to join the National Institutes of Health (NIH) in the Accelerating Medicines Partnership (AMP) launched today to speed new paths to treatment for lupus and autoimmune diseases. The new $230 million collaboration will harness the collective knowledge and resources...

2014-02-04 12:27:31

Lupus Foundation of America Joins a Five-Year Initiative to Bring Together Government, Academia, Industry and Nonprofit Health Organizations to Harness Capabilities and Resources WASHINGTON, Feb. 4, 2014 /PRNewswire-USNewswire/ -- The Lupus Foundation of America will partner with the Foundation for the National Institutes of Health (FNIH) to support a new five-year initiative that will accelerate the ability to develop new medicines for lupus and other diverse and complex diseases....

2014-01-08 08:28:37

HERZLIYA, Israel, January 8, 2014 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) (TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today announced it has signed a licensing agreement with Yeda Research and Development Company Ltd. ("Yeda") to develop hCDR1, a Phase II-ready asset for the treatment of...


Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.